Jaguar Health Converts Preferred Stock to Common at 3.209 Ratio, $2.68 Cash Payout
JAGX•Jaguar Health converted Series O convertible preferred stock into 3.209 common shares per preferred on June 25 at 12:00pm ET, paying cash for fractional interests at $2.68 per share. The company continues its crofelemer program for MVID and SBS-IF, targeting Breakthrough Therapy designation and an NDA filing in H1 2027.
1. Conversion Details
On June 25 at 12:00pm ET, each share of Series O convertible preferred stock automatically converted into 3.209 shares of common stock. Fractional interests were settled in cash at $2.68 per share, based on the June 24 closing price, with no action required by preferred holders.
2. Crofelemer Development Program
Jaguar maintains focus on its crofelemer powder-for-oral-solution trials in microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). The company is pursuing Breakthrough Therapy designation and plans to file a New Drug Application for MVID in the first half of 2027.
